PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD

Read More